← Eichor
Condition: Recurrent Oral Cavity Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Oral Cavity Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Ca
Phase 3 · 205 location(s) · Merus B.V. · NCT06525220BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squ
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06448026First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Phase 2 · 100 location(s) · National Cancer Institute (NCI) · NCT07195734Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest
Phase 2 · 1 location(s) · Mayo Clinic · NCT06997068Gross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers
NA · 3 location(s) · Dr.Pankaj Chaturvedi · NCT04809324A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07063212Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT04754321Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
Phase N/A · 4 location(s) · Vanderbilt University Medical Center · NCT00898638Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT07156227Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Ch
Phase 2 · 178 location(s) · National Cancer Institute (NCI) · NCT04671667Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spre
Phase 3 · 192 location(s) · National Cancer Institute (NCI) · NCT065898045-Fluorouracil Response and Optimization STudy (The FROST Trial)
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT07419464Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent a
Phase 2 · 13 location(s) · NATCO Pharma Ltd. · NCT05283226Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objective
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT01365169FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos,
Phase 2/Phase 3 · 203 location(s) · Bicara Therapeutics · NCT06788990Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread
NA · 1 location(s) · Kolhapur Cancer Centre - Cancer Centers of America · NCT07726199CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Phase 1/Phase 2 · 1 location(s) · Glenn J. Hanna · NCT05774899TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous
Phase 1 · 2 location(s) · Emory University · NCT06868433A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurre
Phase 3 · 22 location(s) · Rakuten Medical, Inc. · NCT06699212Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radi
NA · 1 location(s) · Emory University · NCT06662058Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i
Phase 2 · 6 location(s) · National Cancer Institute (NCI) · NCT06980038Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 · 2 location(s) · Emory University · NCT06636734Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT01473784Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Canc
Phase 1/Phase 2 · 7 location(s) · Faeth Therapeutics · NCT07558733
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.